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cost was 16 USD in group A and 11.43 USD in group B. Con-
clusions: In this series of 39 patients the efﬁcacy of the single daily
dose of levoﬂoxacin was equivalent to the combination of ciclos-
porin plus amoxicilin as bacterial prophylaxis. A daily dose of
levaquin is more convenient and cheaper than the combination
therapy.
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G-CSF(FILGRASTIM) ON DAY 1 (DAY BEFORE STEM CELL INFUSION)
PROVIDES STABLE ENGRAFTMENT AND GOOD PROGRESSION FREE
AND OVERALL SURVIVAL (PFS AND OS) IN HEMATOPOEITIC STEM
CELL TRANSPLANTATION (HSCT)-TATA MEMORIAL CENTRE EXPERI-
ENCE
Bakshi, A.1, Sastry, P.S.R.K.1, Narayanan, P.1, Bhagwat, R.M.1,
Biswas, G.1, Mishra, B.1, Khadwal, A.1, Parikh, P.1 1Tata Memorial
Centre, Mumbai, Maharashtra, India.
Background: Recombinant human G-CSF hastens neutrophil
recovery following hematopoietic stem cell transplantation
(HSCT), thus accelerating engraftment.The optimal timing for
use of G-CSF in conjunction to HSCT needs to be established.We
present our data on effects of adding an extra dose of G-CSF
(ﬁlgrastim 5 micro gm/kg) on day -1 of HSCT. Patients and
Methods: Forty three consecutive patients who underwent HSCT
in one year period were given G-CSF on day 1 (day before stem
cell infusion) in addition to the regular doses from day 1 till
engraftment. Results: Among the 43 patients (median age 36
years), males were 34 and females 9 with 19 allograft and 24
autografts. The type of harvest was PBSC in 39, BM alone in 1 and
both in 3 cases. Disease wise distribution was AML-13, MM-8,
ALL-1, NHL-6, HL-5, CML-5, MDS-2, Aplastic Anemia, ALL,
and Ca nasopharynx 1 each. The median MNC and CD 34 doses
infused were 5.3  108/Kg and 2.26  106/Kg, respectively. Me-
dian days of Grade IV neutropenia was 11 (range 5–19) and that of
ANC 100 was 6 (range 2–19). Neutropenic fever was present for
a median of 10 days (range 4–19). Neutrophil engraftment and
platelet engraftment occurred at day 11(range 8–21) and day
21(range 11–73), respectively. Median number of packed cells
and platelets (SDP) transfused were 4 and 5, respectively. Mucosi-
tis was present for a median of 9 days with Grade III in 51% (n 
22) and Grade IV in 20% (n  9) patients. TPN was used in 76%
(n  33) patients with a median of 5 days. Median number of days
of antibiotics use was 10%, and 58% (n  25) needed 3 lines of
antibiotics. Antifungals were used in 60% (n  26), and 96% of its
use was empirical. Infections were documented in 40% (n  17).
Median days of hospitalization was 23 (range 13–38). Transplant
related mortality was 11.6% (2 auto and 3 allo). At 7 months the
overall survival is 78% with median follow up of 3.5 months.
Conclusions: Addition of G-CSF on day -1 of HSCT is safe and
provides stable engraftment and acceptable results in terms of
neutropenic fever, requirement of blood products, antibiotics,
TPN, and duration of hospital stay. Further randomized trials
comparing conventional scheduling of G-CSF (post infusion day
1 onwards) with the present schedule are warranted.
417
PEGFILRASTIM FOR HEMATOPOIETIC RECOVERY AFTER AUTOLOGOUS
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
Patel, S.1, Sethi, S.1, Holter, J.1, Selby, G.1 1University of Oklahoma
Health Sciences Center, Oklahoma City, OK.
Filgrastim (FIL), granulocyte-colony stimulating factor, reduces
time to neutrophil engraftment, hospital stay, and antibiotic therapy.
FIL requires uncomfortable and inconvenient daily subcutaneous
(SC) injections. Pegﬁlgrastim (PFIL), while more expensive, requires
a single SC injection. Method/Results: An ongoing Phase II trial
compares PFIL 6 mg SC starting day 1 to FIL 480 mcg SC daily
starting day7 historical controls. Nine patients have been accrued to
date (10/10/05) (multiple myeloma 1; NHL 4; HD 4). Thirty
consectutive patients (MM 4; NHL 14; HD 12) were analyzed
as historical controls. ANC 500/mm3 was reached on the mean day
10 (range 9–12) for PFIL and day 12 (range 9–19) for FIL.
Platelets 50 K/mm3 were attained on a mean of day 13 (range
9–21) for PFIL versus day 27 (range 11–63) for FIL. No PFIL
patients required additional G-CSF. One patient had prolonged fever,
probably PFIL-related. Average cost of PFIL was $2681/patient;
average FIL cost was $2736/patient. Conclusions: Preliminary anal-
ysis indicates the equivalency of PFIL and FIL related to hematopoi-
etic recovery. Collection of engraftment, economic, and length-of-
stay data continues.
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THE DEVELOPMENT OF A SUCCESSFUL SATELLITE BONE MARROW
TRANSPLANT (BMT) UNIT AS A MODEL FOR HEALTH CARE OUTREACH
Schriber, J.1,2, Alvarnas, J.1,2, Kendrick, S.1, Dimpfel, S.1,
Sarkodee-Adoo, C.1,2, Forman, S.1,2 1. City of Hope Samaritan BMT
Unit, Phoenix, AZ; 2. City of Hope, Duarte, CA.
Recent innovations have expanded and evolved the ﬁeld of stem
cell transplantation. These changes and the increased complexity
of the ﬁeld have largely limited transplantation to traditional
academic centers. Despite being the ﬁfth largest metropolitan
city in the United States, in 1997 patients who lived in Phoenix,
Arizona, who required transplantation were required to travel
approximately 120 miles to the nearest transplant center. At that
time, prompted by local physicians, the Banner Health System
(the largest oncology provider in the city) partnered with the
City of Hope National Medical Center (COH), a nationally
recognized transplant center located in Duarte, California, to
form the City of Hope Samaritan BMT unit (COHS), a joint
venture between the 2 parties designed to build on each other’s
strengths. The COH provides the local physicians medical lead-
ership, clinical trials, and expertise with biomedical statistics.
Banner Health provides the physical structure, local adminis-
trative support, nursing, and all ancillary care services. The
programs are clinically fully integrated. Patients are discussed at
new patient conference via teleconference, pathology is re-
viewed at the COH, donor choices are made in cooperation with
the COH team, and patients are enrolled on joint clinical trials.
In addition, the Phoenix COH physicians actively participate in
disease committees and in weekly research rounds via telecon-
ference. COHS initially performed only autologous transplants
but now offers all forms of transplant services. To date 470
patients ( auto n  334, sibling allogeneic n  80, MUD n  55,
cord blood n  1) have been transplanted. In the past 2 years
approximatley 40% of patients underwent allogeneic transplan-
tation. Patient demographics are similar between the 2 institu-
tions. The 100 day transplant related mortality for the COHS
compares favorably to the COH (auto 1 vs 2%, allo 4 vs 8%, and
MUD 24 vs 29%). COHS is part of the CTN trials network
through its association with COH and is a member of the
SWOG. The program achieved full FACT accreditation in 2003
prior to the parent organization at COH. The success of this
model has been achieved because of similar corporate cultures,
close clinical integration, and oversight from a board composed
of members from each of the parent organization. We believe
this model can successfully be replicated if the parent organi-
zations share similar cultures and are committed to integrating
the programs clinically.
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